Evotec SE EVO
1.32 USD -0.13 (-8.97%)
Regular-session close
1.34 +0.02 +1.52%
After hours · Nov 20, 5:47 PM ET
1.32 Day range 1.38
1.32 52-week range 3.87
- YTD
- -57.14%
- 1 year
- -54.48%
News
benzinga.com Evotec, Bristol Myers Squibb Protein Degradation Partnership Receives Second FDA Investigational New Drug Acceptance For CELMoD Candidate, Phase 1 Expected In 2027 FDA clearance expands partnered molecular glue pipelineAchievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high…
prnewswire.com Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance FDA clearance expands partnered molecular glue pipeline Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high…
gurufocus.com Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell TechnologyPR NewswireHAMBURG, Germany, Nov. 16, 2026New three-yearbenzinga.com Evotec Lands $2.9M Gates Foundation Grant Giving Global Health Researchers Continued Access To Stem Cell Platform For Early Drug Safety Assessment New three-year grant from the Gates Foundation extends a 2023 project to help global health researchers predict potential fetal development risks posed by novel drug candidatesEvotec's human stem…
prnewswire.com Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology New three-year grant from the Gates Foundation extends a 2023 project to help global health researchers predict potential fetal development risks posed by novel drug candidates Evotec's human stem…benzinga.com HC Wainwright & Co. Maintains Buy on Evotec, Raises Price Target to $5 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Evotec (NASDAQ:EVO) with a Buy and raises the price target from $4 to $5.
benzinga.com Evotec Affirms FY2026 Sales Guidance of $656.004M-$702.039M vs $681.980M Est Evotec (NASDAQ:EVO) affirms FY2026 sales outlook from $656.004 million-$702.039 million to $656.004 million-$702.039 million vs $681.980 million estimate.
benzinga.com Evotec Q3 EPS €(0.15) Misses €(0.14) Estimate Evotec (NASDAQ:EVO) reported quarterly losses of €(0.15) per share which missed the analyst consensus estimate of €(0.14) by 7.14 percent. This is a 40 percent increase over losses of €(0.25) per…
benzinga.com Evotec Q3 Sales €164.926M Miss €167.080M Estimate Evotec (NASDAQ:EVO) reported quarterly sales of €164.926 million which missed the analyst consensus estimate of €167.080 million by 1.29 percent. This is a 0.63 percent increase over sales of…
